SMH vs XBI
VanEck Semiconductor ETF vs SPDR S&P Biotech ETF
- • XBI pays a higher dividend yield (0.34%).
Side-by-side metrics
| Metric | SMH | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.35% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.22% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $58.79B | $8.30B |
YTD return | 52.66% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.82 | 1.09 |
P/E ratio | 44.45 | — |
Last price | $540.10 | $133.66 |
Inception | — | — |
Issuer | VanEck | State Street |
SMH top holdings
| NVDA | NVIDIA Corp | 18.09% |
| TSM | Taiwan Semiconductor Manufacturing Co Ltd ADR | 10.59% |
| AVGO | Broadcom Inc | 7.83% |
| INTC | Intel Corp | 7.14% |
| AMD | Advanced Micro Devices Inc | 5.95% |
| MU | Micron Technology Inc | 4.98% |
| TXN | Texas Instruments Inc | 4.90% |
| KLAC | KLA Corp | 4.49% |
| ADI | Analog Devices Inc | 4.41% |
| LRCX | Lam Research Corp | 4.11% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About SMH
SMH (VanEck Semiconductor ETF) is 25 largest semiconductor companies. Managed by VanEck, the fund carries $58.8B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.22%. Its largest holding is NVIDIA Corp (NVDA), which represents 18.1% of the portfolio. Technology is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.